

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/780,819	02/18/2004	William A. Schumacher	HA0793 NP	3774
23914 75	90 10/16/2006	EXAMINER		
LOUIS J. WIL		KWON, BRIAN YONG S		
PATENT DEPA	ERS SQUIBB COMPANY ARTMENT	ART UNIT	PAPER NUMBER	
P O BOX 4000		1614		
PRINCETON,	NJ 08543-4000		DATE MAILED: 10/16/2006	5 .

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No	э.	Applicant(s)					
Office Action Summary		10/780,819		SCHUMACHER ET AL.					
		Examiner		Art Unit					
		Brian S. Kwon		1614					
Period fo	The MAILING DATE of this communication or Reply	appears on the cov	er sheet with the c	orrespondence ad	Idress				
WHIC - Externafter - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING STATE OF THE PROPERTY OF THE MAILING STATE OF THE PROPERTY OF THE	B DATE OF THIS C R 1.136(a). In no event, ho riod will apply and will expir atute, cause the application	COMMUNICATION wever, may a reply be tim re SIX (6) MONTHS from to to become ABANDONED	L. the mailing date of this c (35 U.S.C. § 133).					
Status									
1)⊠	Responsive to communication(s) filed on 18	8 February 2004.							
	This action is FINAL . 2b) This action is non-final.								
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is								
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)🖂	4)⊠ Claim(s) <u>1-17</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)	5) Claim(s) is/are allowed.								
6)	Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.								
8)⊠	8) Claim(s) 1-17 are subject to restriction and/or election requirement.								
Applicati	on Papers								
9) 🗌	The specification is objected to by the Exam	iner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.									
	Applicant may not request that any objection to t	the drawing(s) be hel	d in abeyance. See	37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).									
11)	The oath or declaration is objected to by the	Examiner. Note th	e attached Office	Action or form P1	ГО-152.				
Priority u	ınder 35 U.S.C. § 119		•						
12)	Acknowledgment is made of a claim for fore	ian nriority under 3	5 U.S.C. & 119(a).	-(d) or (f)	•				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:									
/-	1. ☐ Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage									
	application from the International Bur	eau (PCT Rule 17.	2(a)).						
* S	ee the attached detailed Office action for a l	list of the certified o	copies not received	d.					
					•				
Attachment	(c)								
_	e of References Cited (PTO-892)	· 4\ [Interview Summary ((PTO-413)					
2) 🔲 Notic	e of Draftsperson's Patent Drawing Review (PTO-948)		Paper No(s)/Mail Dat	te	. 4				
	nation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date <u>04/29/04</u> .	5) <u> </u> 6) [Notice of Informal Pa Other:	atent Application	-				

Application/Control Number: 10/780,819

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-10, drawn to a method of treating thrombosis, comprising administering to a patient a pharmaceutical composition comprising a small organic factor compound.
 - II. Claims 11-17, drawn to a method of inhibiting Factor XIa by administering a small organic compound.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, Invention I can be practiced with different mode operation or underlying mechanism, for example by inhibiting plasminogen activator, modulating RXR receptor, promoting angiogenesis and inhibiting tyrosine kinase.

Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

2. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, for example the specific compound from Table 1, under the instant claims of the elected Group. Moreover, whatever specific compound is ultimately elected, applicants are required to list all claims readable thereon.

With the election of a specific exemplified compound, a generic concept will be identified by the examiner as the inventive group for examination.

Application/Control Number: 10/780,819

Art Unit: 1614

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see http://pair-direct.uspto.gov Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Brian Kwon

Primary Patent Examiner AU 1614